



Announcement Summary

Name of entity
AUSTRALIAN CLINICAL LABS LIMITED

Announcement type
Update announcement

Type of update
Correction to previous announcement

Date of this announcement
29/8/2024

Reason for update

To fix an auto-correction of ACL in Box 3D.1
--

ASX Security code and description of the class of +securities the subject of the buy-back
ACL : ORDINARY FULLY PAID

The type of buy-back is:
On market buy-back
Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

AUSTRALIAN CLINICAL LABS LIMITED

We (the entity named above) provide the following information about our buy-back.

1.2 Registration number type

ABN

Registration number

94645711128

1.3 ASX issuer code

ACL

1.4 The announcement is

Update/amendment to previous announcement

1.4a Type of update

Correction to previous announcement

1.4b Reason for update

To fix an auto-correction of ACL in Box 3D.1

1.4c Date of initial notification of buy-back

29/8/2024

1.4d Date of previous announcement to this update

29/8/2024

1.5 Date of this announcement

29/8/2024

1.6 ASX Security code and description of the class of +securities the subject of the buy-back

ACL : ORDINARY FULLY PAID



Part 2 - Type of buy-back

2.1 The type of buy-back is:

On market buy-back



Part 3 - Buy-back details

Part 3A - Details of +securities, price and reason

3A.1 Total number of +securities on issue in the class of +securities to be bought back

201,834,015

3A.4 Does the entity intend to buy back a minimum number of +securities

No

3A.5 Does the entity intend to buy back a maximum number of securities

Yes

3A.5a Maximum number of securities proposed to be bought back

20,000,000

3A.6 Name of broker or brokers who will offer to buy back +securities on the entity's behalf

Broker name:

To be confirmed

3A.9 Are the +securities being bought back for a cash consideration?

Yes

3A.9a Is the price to be paid for +securities bought back known?

No

3A.9a.1 In what currency will the buy-back consideration be paid?

AUD - Australian Dollar

Part 3B - Buy-back restrictions and conditions

3B.1 Does the buy-back require security holder approval?

No



Part 3C - Key dates

On-market buy-back

3C.2 Proposed buy-back start date

16/9/2024

3C.3 Proposed buy-back end date

15/9/2025

Part 3D - Other Information

3D.1 Any other information the entity wishes to notify to ASX about the buy-back

The buy back is subject to prevailing share price, ACL's ongoing capital position and other relevant factors. ACL reserves the right to suspend or terminate the buy-back at any time. The total amount of the buy back, and the timing of purchases, will be subject to the Board's ongoing view on what is most beneficial to the efficient capital management of the company. There is no certainty that ACL will acquire any or the maximum shares under the buy-back.